Pharma Focus Asia
KP - Choose our fully recyclable blister films

Huntsman Cancer Institute at the University of Utah Develops Novel Prostate Cancer Therapy

Huntsman Cancer Institute received approval from the U.S. Food and Drug Administration (FDA) for a new prostate cancer treatment that combines two cancer drugs, enzalutamide and talazoparib.

Enzalutamide is a medication commonly used for prostate cancer treatment, but the addition of talazoparib is a novel approach specifically for patients with prostate cancer. 

The phase 3 trial demonstrated that this drug combination led to a 55 percent reduction in the risk of cancer progression compared to the standard treatment available for these patients.

The novel therapy signifies an improved outlook for many patients and underscores the dedication of researchers and healthcare professionals to enhance cancer treatments and alleviate the burden of the disease.

Prostate cancer is one of the most prevalent cancer types, and it ranks as the second leading cause of cancer-related deaths among men in the United States, according to the National Cancer Institute.

The approval of this new prostate cancer therapy combining enzalutamide and talazoparib represents a significant milestone in the field of cancer treatment.

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayThermo Fisher Scientific - PeptonesMerck - Mobius® products5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024